Seattle Genetics

Seattle Genetics Hits $30 Million Milestone With European Approval of Adcetris in Frontline Hodgkin Lymphoma
CP Wire
Mon, 02/11/19 - 10:20 am
Seattle Genetics
Adcetris
Takeda Pharmaceuticals
Hodgkin's lymphoma
Seattle Genetics Hits $30 Million Milestone With European Approval of Adcetris in Frontline Hodgkin Lymphoma
Mon, 02/11/19 - 10:20 am
Seattle Genetics
Adcetris
Takeda Pharmaceuticals
Hodgkin's lymphoma
Seattle Genetics down on light 2019 Adcetris sales guidance
BioCentury
Sat, 02/9/19 - 12:19 am
Seattle Genetics
Adcetris
ASH: Seattle Genetics rolls into latest Adcetris launch with double survival win
Fierce Biotech
Tue, 12/4/18 - 09:41 am
Seattle Genetics
Adcetris
ASH 2018
T-cell lymphoma
Adcetris gets speedy label expansion under FDA real-time pilot
BioCentury
Sat, 11/17/18 - 12:37 pm
FDA
Adcetris
Seattle Genetics
label expansions
Seattle Genetics Submits Supplemental BLA for Adcetris in T-Cell Lymphomas
CP Wire
Mon, 11/5/18 - 11:19 am
Seattle Genetics
Adcetris
T-cell lymphoma
Seattle Genetics Submits Supplemental BLA for Adcetris in T-Cell Lymphomas
Mon, 11/5/18 - 10:08 am
Seattle Genetics
Adcetris
T-cell lymphoma
Seattle Genetics sags as Adcetris sales miss target
BioCentury
Fri, 10/26/18 - 08:34 pm
Seattle Genetics
earnings
Adcetris
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
Sat, 10/20/18 - 11:16 pm
earnings
biotech
Biogen
Alexion Pharmaceuticals
Bristol-Myers Squibb
Celgene
Gilead Sciences
Merck
Biomarin
Galapagos
Seattle Genetics
Dr Reddy's
Seattle Genetics' Adcetris Has Potential to Change Treatment for T-Cell Lymphoma
BioSpace
Mon, 10/8/18 - 11:36 pm
Seattle Genetics
Takeda
Adcetris
peripheral T-cell lymphoma
Seattle Genetics' and Takeda's Adcetris Meets Primary and Secondary Endpoints in Ph III Trial for T-Cell Lymphoma
CP Wire
Mon, 10/1/18 - 09:40 am
Seattle Genetics
Takeda
Adcetris
T-cell lymphoma
Seattle Genetics' and Takeda's Adcetris Meets Primary and Secondary Endpoints in Ph III Trial for T-Cell Lymphoma
Mon, 10/1/18 - 09:33 am
Seattle Genetics
Takeda
Adcetris
T-cell lymphoma
Seattle Genetics: 2Q Earnings Snapshot
San Francisco Chronicle, CA
Sun, 07/29/18 - 10:57 am
Seattle Genetics
earnings
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
CP Wire
Thu, 07/12/18 - 09:17 am
Seattle Genetics
colorectal cancer
non-small cell lung cancer
pancreatic cancer
head and neck cancer
cervical cancer
tisotumab vedotin
Genmab
clinical trials
Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer
CP Wire
Wed, 07/11/18 - 10:12 am
Seattle Genetics
tucatinib
orphan drugs
clinical trials
HER2-positive metastatic breast cancer
breast cancer
Seattle Genetics Announces Results of Two Ph II Trials of Tucatinib in HER2- Positive Metastatic Breast Cancer
Wed, 07/11/18 - 09:37 am
Seattle Genetics
tucatinib
breast cancer
HER2-positive metastatic breast cancer
Seattle Genetics Accelerates Revenue Growth, Earnings Not So Much
Motley Fool
Wed, 05/2/18 - 09:58 pm
Seattle Genetics
earnings
Why Seattle Genetics Jumped Higher Today
Motley Fool
Fri, 04/27/18 - 08:06 pm
Seattle Genetics
earnings
Adcetris
Seattle Genetics Gains Another FDA Approval
BioSpace
Thu, 03/22/18 - 09:00 am
Seattle Genetics
FDA
Adcetris
Hodgkin's lymphoma
3 Things In Biotech, March 8: A Tale Of 3 New Trials
Seeking Alpha
Sat, 03/10/18 - 09:26 am
biotech
clinical trials
Seattle Genetics
SGN-CD48A
Daiichi Sankyo
DS-8201
HER-positive colorectal cancer
Allena Pharmaceuticals
hyperoxaluria

Pages